miRNA Plasmid Composition for Target mRNA Degradation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulated production of bioactive molecules such as complements and factors leads to homeostatic imbalance, resulting in disease, and existing therapies are inadequate for effectively regulating their expression.
Innovation Solution
Compositions comprising recombinant plasmids that encode for micro-interfering ribonucleic acid (miRNA) sequences, which target and degrade or inactivate the mRNA of specific biomolecules like complements and factors, thereby downregulating their production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to regulate bioactive molecule expression, then treatment is provided, but the regulation effectiveness is inadequate
Solution Approach 1:
The patent introduces miRNA molecules as intermediary agents that specifically bind to target mRNA sequences of bioactive molecules (complements and factors). This intermediary mechanism enables precise post-transcriptional regulation by degrading or blocking translation of specific mRNAs, thereby achieving effective downregulation of over-expressed bioactive molecules without affecting other physiological processes.
Solution Approach 2:
The patent changes the regulatory parameter from transcriptional control to post-transcriptional control via miRNA-mediated mRNA degradation or translational inhibition. This parameter change allows for more precise and adaptable regulation of bioactive molecule expression levels, addressing the inadequacy of existing therapies.
2Stability of the object's composition
If miRNA production is upregulated to decrease target biomolecule bioavailability, then homeostasis is restored, but the complexity of the composition increases
Solution Approach 1:
The patent employs endogenous miRNA molecules that are naturally produced within the subject's cells. After administration of the plasmid composition, the host cell's own transcriptional and translational machinery is harnessed to produce the therapeutic miRNAs. This self-service approach simplifies the overall system by utilizing the body's existing biological infrastructure rather than requiring complex external delivery or synthesis systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively upregulate miRNA production within cells, leading to decreased bioavailability of target biomolecules and restoring homeostasis, thus preventing or treating associated diseases.
Implementation Method 1
The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.